• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表观遗传修饰对肝脏疾病发生发展的影响及其作用机制。

The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism.

机构信息

Chinese Medicine Modernization and Big Data Research Center, Nanjing Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

Department of Pharmacology, School of Integral Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

出版信息

Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):259-270. doi: 10.1080/17474124.2020.1736042. Epub 2020 Mar 3.

DOI:10.1080/17474124.2020.1736042
PMID:32124651
Abstract

: Epigenetic modification is a type of gene expression and regulation that does not involve changes in DNA sequences. An increasing number of studies have proven that epigenetic modifications play an important role in the occurrence and progression of liver diseases through the gene regulation and protein expressions of hepatocellular lipid metabolism, inflammatory reaction, cell proliferation, and activation, etc.: In this study, we elaborated and analyzed the underlying functional mechanism of epigenetic modification in alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), liver fibrosis (LF), viral hepatitis, hepatocellular carcinoma (HCC), and research progress of recent years.: The further understanding of epigenetic mechanisms that can regulate gene expression and cell phenotype leads to new insights in epigenetic control of chronic liver disease. Currently, hepatologists are exploring the role of DNA methylation, histone/chromatin modification, and non-coding RNA in specific liver pathology. These findings have led to advances in direct epigenetic biomarker testing of patient tissue or body fluid specimens, as well as quantitative analysis. Based on these findings, drug validation of some targets involved in the epigenetic mechanism of liver disease is gradually being carried out clinically.

摘要

表观遗传修饰是一种基因表达和调控的方式,不涉及 DNA 序列的变化。越来越多的研究证明,表观遗传修饰通过肝细胞脂质代谢、炎症反应、细胞增殖和活化等方面的基因调控和蛋白表达,在肝脏疾病的发生和进展中发挥重要作用:本研究详细阐述和分析了表观遗传修饰在酒精性肝病 (ALD)、非酒精性脂肪性肝病 (NAFLD)、肝纤维化 (LF)、病毒性肝炎、肝细胞癌 (HCC)中的作用机制,并对近年来的研究进展进行了分析。:对能够调节基因表达和细胞表型的表观遗传机制的进一步了解,为慢性肝病的表观遗传调控提供了新的见解。目前,肝病学家正在探索 DNA 甲基化、组蛋白/染色质修饰和非编码 RNA 在特定肝脏病理中的作用。这些发现促进了对患者组织或体液标本进行直接表观遗传生物标志物检测和定量分析。基于这些发现,一些涉及肝病表观遗传机制的靶点的药物验证正在逐步在临床上进行。

相似文献

1
The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism.表观遗传修饰对肝脏疾病发生发展的影响及其作用机制。
Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):259-270. doi: 10.1080/17474124.2020.1736042. Epub 2020 Mar 3.
2
Non-coding RNAs as direct and indirect modulators of epigenetic mechanism regulation of cardiac fibrosis.非编码RNA作为心脏纤维化表观遗传机制调控的直接和间接调节因子
Expert Opin Ther Targets. 2015 May;19(5):707-16. doi: 10.1517/14728222.2014.1001740. Epub 2015 Feb 4.
3
Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer.非编码 RNA 在食管癌表观遗传修饰中的作用。
Biomed Pharmacother. 2019 Sep;117:109192. doi: 10.1016/j.biopha.2019.109192. Epub 2019 Jul 11.
4
Epigenetic regulation of hepatic stellate cell activation and liver fibrosis.肝星状细胞激活与肝纤维化的表观遗传调控
Expert Rev Gastroenterol Hepatol. 2016 Dec;10(12):1397-1408. doi: 10.1080/17474124.2016.1251309. Epub 2016 Nov 2.
5
Epigenetic regulation of liver fibrosis.肝纤维化的表观遗传调控
Clin Res Hepatol Gastroenterol. 2015 Sep;39 Suppl 1:S64-8. doi: 10.1016/j.clinre.2015.05.013. Epub 2015 Jul 16.
6
Emerging roles of non-coding RNAs in epigenetic regulation.非编码 RNA 在表观遗传调控中的新兴作用。
Sci China Life Sci. 2016 Mar;59(3):227-35. doi: 10.1007/s11427-016-5010-0. Epub 2016 Jan 29.
7
Potential epigenetic mechanism in non-alcoholic Fatty liver disease.非酒精性脂肪性肝病中的潜在表观遗传机制。
Int J Mol Sci. 2015 Mar 5;16(3):5161-79. doi: 10.3390/ijms16035161.
8
Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis.肝星状细胞中的表观遗传修饰有助于肝纤维化。
Tohoku J Exp Med. 2013 Jan;229(1):35-43. doi: 10.1620/tjem.229.35.
9
New Insights into the Role of Histone Changes in Aging.衰老过程中组蛋白变化作用的新见解。
Int J Mol Sci. 2020 Nov 3;21(21):8241. doi: 10.3390/ijms21218241.
10
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease.代谢相关脂肪性肝病的表观遗传药物发现全景。
Trends Genet. 2020 Jun;36(6):429-441. doi: 10.1016/j.tig.2020.03.003. Epub 2020 Mar 28.

引用本文的文献

1
Differentially expressed and alternately spliced genes as a novel tool for genotoxicity: a computerized study in ATT-myc transgenic mice for the recognition of genotoxic and non-genotoxic chemical.差异表达和可变剪接基因作为遗传毒性的一种新工具:在ATT - myc转基因小鼠中进行的一项计算机化研究,用于识别遗传毒性和非遗传毒性化学物质。
Front Genet. 2025 Mar 28;16:1505379. doi: 10.3389/fgene.2025.1505379. eCollection 2025.
2
Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight.代谢功能障碍相关脂肪性肝病诱导的肝细胞癌中表观遗传学与代谢重编程之间的串扰:新视角
Metabolites. 2024 Jun 8;14(6):325. doi: 10.3390/metabo14060325.
3
Comparative hepatotoxicity of novel lithium bis(trifluoromethanesulfonyl)imide (LiTFSI, ie. HQ-115) and legacy Perfluorooctanoic acid (PFOA) in male mice: Insights into epigenetic mechanisms and pathway-specific responses.
新型双(三氟甲烷磺酰基)亚胺锂(LiTFSI,即 HQ-115)与传统全氟辛酸(PFOA)在雄性小鼠中的肝毒性比较:表观遗传机制与特定途径反应的深入研究。
Environ Int. 2024 Mar;185:108556. doi: 10.1016/j.envint.2024.108556. Epub 2024 Mar 7.
4
JMJD2D stabilises and cooperates with HBx protein to promote HBV transcription and replication.JMJD2D与乙肝病毒X蛋白(HBx)稳定结合并协同作用,以促进乙肝病毒的转录和复制。
JHEP Rep. 2023 Jul 15;5(10):100849. doi: 10.1016/j.jhepr.2023.100849. eCollection 2023 Oct.
5
Insights into the role of nucleotide methylation in metabolic-associated fatty liver disease.核苷酸甲基化在代谢相关性脂肪性肝病中的作用研究进展。
Front Immunol. 2023 Mar 20;14:1148722. doi: 10.3389/fimmu.2023.1148722. eCollection 2023.
6
Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring.非酒精性脂肪性肝病及其遗传、表观遗传和环境因素对子代的影响。
World J Gastroenterol. 2022 Jul 7;28(25):2890-2899. doi: 10.3748/wjg.v28.i25.2890.
7
Epigenetic Aspects and Prospects in Autoimmune Hepatitis.自身免疫性肝炎的表观遗传学方面及展望。
Front Immunol. 2022 Jun 30;13:921765. doi: 10.3389/fimmu.2022.921765. eCollection 2022.
8
Editorial: Alcohol Consumption and Liver Diseases: From Pathology to Phytotherapy.社论:酒精消费与肝脏疾病:从病理学到植物疗法
Front Pharmacol. 2022 Feb 16;13:848334. doi: 10.3389/fphar.2022.848334. eCollection 2022.
9
Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease.慢性肝病中组蛋白修饰的机制与治疗机遇
Front Pharmacol. 2021 Nov 23;12:784591. doi: 10.3389/fphar.2021.784591. eCollection 2021.
10
Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD.非酒精性脂肪性肝病纤维化进展过程中 DNA 甲基化差异和细胞类型比例变化。
Clin Epigenetics. 2021 Aug 5;13(1):152. doi: 10.1186/s13148-021-01129-y.